Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lo

Showing results (361-370 of 386) with videos related to

Pageof 39
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaAdriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2026
Ethnic-specific effects of the LILRB2-LILRB5 locus and newly identified risk loci for Alzheimer's disease in the East Asian populationHan Cao, Ziyu Zheng, Xiaopu Zhou, et al.
The Lancet. Oncology|May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort studyInes Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 30, 2026
Targeted blood proteome profiling using NULISAseq identifies a high-performance biomarker panel for Aβ pathology quantification and stagingWenyue Zheng, Yuanbing Jiang, Hiu Yi Wong, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2026
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experienceFrancis Proulx-Rocray, Rebecca Symons, Yang Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2025
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell CarcinomaJeremy Mo, Anne Zaremba, Andrisha-Jade Inderjeeth, et al.
Nature Communications|December 9, 2022
SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signalingScott B Biering, Francielle Tramontini Gomes de Sousa, Laurentia V Tjang, et al.
Pageof 39

Showing results (361-370 of 386) with videos related to

Sort By:
Pageof 39
European Journal of Cancer (Oxford, England : 1990)|November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaAdriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2026
Ethnic-specific effects of the LILRB2-LILRB5 locus and newly identified risk loci for Alzheimer's disease in the East Asian populationHan Cao, Ziyu Zheng, Xiaopu Zhou, et al.
The Lancet. Oncology|May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort studyInes Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 30, 2026
Targeted blood proteome profiling using NULISAseq identifies a high-performance biomarker panel for Aβ pathology quantification and stagingWenyue Zheng, Yuanbing Jiang, Hiu Yi Wong, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2026
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experienceFrancis Proulx-Rocray, Rebecca Symons, Yang Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2025
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell CarcinomaJeremy Mo, Anne Zaremba, Andrisha-Jade Inderjeeth, et al.
Nature Communications|December 9, 2022
SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signalingScott B Biering, Francielle Tramontini Gomes de Sousa, Laurentia V Tjang, et al.
Pageof 39